(Q42878733)

9 November 2017

Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer (English)

1 reference

9 November 2017

1 reference

1 reference

C Mao

1

1 reference

9 November 2017

R-Y Liao

series ordinal

2

1 reference

9 November 2017

Q Chen

series ordinal

3

1 reference

9 November 2017

language of work or name

English

0 references

publication date

16 February 2010

1 reference

British Journal of Cancer

9 November 2017

1 reference

9 November 2017

102

1 reference

9 November 2017

5

1 reference

9 November 2017

940

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605575

9 November 2017

0 references

cites work

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833261

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833261

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833261

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833261

16 August 2018

Identifiers

DOI

10.1038/SJ.BJC.6605575

1 reference

9 November 2017

1 reference

9 November 2017

1 reference